Guardant Health (GH) Scheduled to Post Quarterly Earnings on Thursday

Guardant Health (NASDAQ:GH) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter. Guardant Health has set its FY 2024 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.65). Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. The firm had revenue of $155.05 million during the quarter, compared to the consensus estimate of $151.71 million. On average, analysts expect Guardant Health to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Guardant Health Stock Up 1.2 %

Shares of NASDAQ:GH opened at $19.10 on Tuesday. The company has a debt-to-equity ratio of 7.18, a current ratio of 6.54 and a quick ratio of 6.24. The business has a 50 day simple moving average of $18.36 and a two-hundred day simple moving average of $22.45. Guardant Health has a 1 year low of $15.81 and a 1 year high of $41.06. The firm has a market capitalization of $2.32 billion, a PE ratio of -4.46 and a beta of 0.92.

Insider Buying and Selling

In related news, insider Kumud Kalia acquired 2,187 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was purchased at an average cost of $17.82 per share, for a total transaction of $38,972.34. Following the purchase, the insider now directly owns 12,722 shares of the company’s stock, valued at approximately $226,706.04. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on GH shares. The Goldman Sachs Group cut their price objective on Guardant Health from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, April 15th. JPMorgan Chase & Co. reduced their price target on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Craig Hallum initiated coverage on shares of Guardant Health in a report on Wednesday, April 24th. They set a “buy” rating and a $28.00 price objective for the company. Piper Sandler dropped their target price on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, February 26th. Finally, Guggenheim reaffirmed a “neutral” rating on shares of Guardant Health in a research note on Friday, April 5th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.70.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.